

11 April 2023

BEIMCO PHARMACEUTICALS LIMITED

Holdings in Company

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBB6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, notes that, following the announcement on 31 March 2023, two shareholders in Bangladesh have reported a further trade between one another in the Company's Ordinary shares, which are only tradeable in Bangladesh, to the Dhaka Stock Exchange on 10 April 2023. This trade does not concern global depositary receipts admitted to trading on AIM in London.

IFIC Securities Limited sold 4m Ordinary shares at a price of TK.135.00 per share to New Dacca Industries Limited who bought the 4m Ordinary shares at a price of TK.135.00 per share between 4 and 10 April 2023.

As a result, IFIC Securities Limited no longer owns a disclosable stake in the Company and New Dacca Industries Limited now holds 14,345,757 Ordinary shares representing 3.22 per cent. of the total voting rights in the Company.

For further information, please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080

Mohammad Asad Ullah FCS
Executive Director & Company Secretary
Tel: 880 2 58611001, Ext. 10140

Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

HOLKZGMDDMRGFZM